Trial reportAnnals of the rheumatic diseases2008
Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis.
Trial report in Annals of the rheumatic diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Pooled it
- Systematic review and network meta-analysis on the efficacy and safety of parmacotherapy for hand osteoarthritis.PloS one · 2024Pooled it
- Pooled it
- Efficacy of corticosteroids for hand osteoarthritis - a systematic review and meta-analysis of randomized controlled trials.BMC musculoskeletal disorders · 2022Pooled it
- Efficacy and safety of corticosteroid in the treatment of hand osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.Clinical rheumatology · 2022Pooled it
- Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.Annals of the rheumatic diseases · 2019Trial
- Advances in the pathology and treatment of osteoarthritis.Journal of advanced research · 2025Review
- Inflammation as a therapeutic target for osteoarthritis: A literature review of clinical trials.Clinical rheumatology · 2024Review
- Report of similar placebo response in one internet versus onsite randomised controlled trials from the literature.Osteoarthritis and cartilage open · 2024Article
- Systematic Review of Non-surgical Therapies for Osteoarthritis of the Hand: An Update.European journal of rheumatology · 2023Article
- Cross-cultural adaptation and validation of the Thai version of the functional index for hand osteoarthritis (FIHOA).BMC musculoskeletal disorders · 2022Article
- Topical corticosteroid for treatment of hand osteoarthritis: study protocol for a randomised controlled trial.BMC musculoskeletal disorders · 2021Article
- Predictors of a placebo response in patients with hand osteoarthritis: post-hoc analysis of two randomized controlled trials.BMC musculoskeletal disorders · 2021Article
- Cross-cultural translation, adaptation and validation of a Japanese version of the functional index for hand osteoarthritis (J-FIHOA).BMC musculoskeletal disorders · 2020Observational
- Article
- Hand osteoarthritis-nonpharmacological and pharmacological treatments.Nature reviews. Rheumatology · 2014Review
- Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigs.Journal of pain research · 2012Article
- The role of synovitis in osteoarthritis.Therapeutic advances in musculoskeletal disease · 2010Article
- Synergistic drug combinations tend to improve therapeutically relevant selectivity.Nature biotechnology · 2009Article
- Time for new outcome measures in hand osteoarthritis?Nature clinical practice. Rheumatology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe novel synergistic drug candidate CRx-102 comprises dipyridamole and low dose prednisolone and is in clinical development for the treatment of immunoinflammatory diseases. The purpose of this clinical study was to examine the efficacy and safety of CRx-102 in patients with hand osteoarthritis (HOA).
methodsThe study was conducted as a blinded, randomised, placebo-controlled trial at four centres in Norway. Eligibility criteria included being of age 30-70 years, at least one swollen and tender joint, a Kellgren-Lawrence (K-L) score of 2 or higher on radiographs, and a score of at least 30 mm pain on the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) visual analogue pain scale (VAS). The primary endpoint was a reduction in pain from baseline to day 42 on the AUSCAN pain subscale. Two-sided p values for the differences in least squares (LS) means adjusted for baseline are presented.
resultsThe mean age of the 83 patients with HOA was 60 years and 93% were females. CRx-102 was statistically superior to placebo at 42 days for changes in AUSCAN pain (LS mean -14.2 vs -4.0) and for clinically relevant secondary endpoints (joint pain VAS (-18.6 vs -6.3), patient global VAS (-15.9 vs -4.2)) in the intention to treat population. The most frequently reported adverse event during the study was headache (52% in CRx-102 vs 15% in the placebo group).
conclusionsThe novel synergistic drug candidate CRx-102 demonstrated efficacy by statistically reducing pain compared to placebo in HOA and was generally well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.